LivaNova (NASDAQ:LIVN) Reaches New 1-Year High – Here’s Why

LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high during trading on Thursday . The stock traded as high as $72.92 and last traded at $72.00, with a volume of 6404 shares. The stock had previously closed at $72.44.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LIVN shares. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Robert W. Baird cut their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Needham & Company LLC boosted their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Mizuho boosted their price target on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, Barclays boosted their price target on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.22.

LivaNova Price Performance

The firm has a market cap of $3.85 billion, a PE ratio of 35.90 and a beta of 0.82. The stock’s fifty day moving average price is $64.25 and its 200-day moving average price is $62.80. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same quarter in the prior year, the firm earned $0.88 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities analysts expect that LivaNova PLC will post 3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently modified their holdings of LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after acquiring an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after acquiring an additional 15,405 shares during the last quarter. Intech Investment Management LLC boosted its position in shares of LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after acquiring an additional 7,195 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of LivaNova during the 1st quarter valued at about $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.